Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

Published:2017-10-22 Issue:3 Volume:38 Page:443-450
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Asselah Tarik¹^ORCID,Bourgeois Stefan²,Pianko Stephen³,Zeuzem Stefan⁴,Sulkowski Mark⁵,Foster Graham R.⁶,Han Lingling⁷,McNally John⁷,Osinusi Anu⁷,Brainard Diana M.⁷,Subramanian G. Mani⁷,Gane Edward J.⁸,Feld Jordan J.⁹^ORCID,Mangia Alessandra¹⁰

Affiliation:

1. Department of Hepatology; Hôpital Beaujon; APHP; INSERM CRI; UMR1149; University Paris-Diderot; Clichy France

2. Campus Stuivenberg; Antwerp Belgium

3. Monash Health and Monash University; Clayton Vic. Australia

4. Johann Wolfgang Goethe University Medical Center; Frankfurt am Main Germany

5. Johns Hopkins University; Baltimore MD USA

6. Queen Mary University London; London UK

7. Gilead Sciences Inc.; Foster City CA USA

8. Auckland Clinical Studies Ltd; Auckland New Zealand

9. Toronto Centre for Liver Disease; Toronto ON Canada

10. Casa Sollievo della Sofferenza Hospital; San Giovanni Rotondo Italy

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13534/fullpdf

Reference24 articles.

1. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis;Cardoso;J Hepatol,2010

2. Outcome of sustained virological responders with histologically advanced chronic hepatitis C;Morgan;Hepatology,2010

3. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C;Dienstag;Hepatology,2011

4. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis;Meer;JAMA,2012

5. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies;Morgan;Ann Intern Med,2013

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with Sofosbuvir/Velpatasvir of the most difficult to cure HCV-infected population;Polish Archives of Internal Medicine;2024-01-02

2. Profile of Sofosbuvir and Velpatasvir Combination in the Treatment of Chronic Hepatitis C in Children and Adolescents: Current Evidence;Therapeutics and Clinical Risk Management;2024-01

3. Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals;Archives of Endocrinology and Metabolism;2024

4. CLINICAL PROFILE AND TREATMENT RESPONSE TO SOFOSBUVIR-VELPATASVIR REGIMEN AND ITS IMPACT ON THE QUALITY OF LIFE IN CHRONIC HEPATITIS C PATIENTS;International Journal of Pharmacy and Pharmaceutical Sciences;2023-09-01

5. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks;Journal of Clinical Virology Plus;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3